Rheumatology · Brooklyn, NY
NPI
1932562550
Since 2016
Specialty
Rheumatology
Code 390200000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
450 Clarkson Ave, Box 1126
Brooklyn, NY, 11203
Phone (718) 270-8867
Groups this clinician bills Medicare through
Medicare paid
-
No Medicare services published
Medicare patients
-
Drug cost, 2024
$670K
998 prescriptions
Company payments
-
None reported
Medicare prescription drug claims, 2024
In 2024, the drug Manjeet S Bhamra prescribed most often to Medicare patients was Prednisone, with 201 prescriptions and refills. In total Manjeet S Bhamra wrote 998 Medicare prescriptions that cost $670K.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-12-20.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Prednisone Generic | 201 | 446 | 92 | $2,501 |
| Hydroxychloroquine Sulfate Generic | 126 | 406 | 47 | $4,349 |
| Methotrexate Methotrexate Sodium | 95 | 274 | 36 | $1,898 |
| Meloxicam Generic | 47 | 128 | 29 | $367 |
| Enbrel Etanercept | 46 | 47 | Under 11 | $222K |
| Allopurinol Generic | 44 | 146 | 18 | $679 |
| Colchicine Generic | 40 | 117 | 21 | $1,479 |
| Amjevita(Cf) Autoinjector Adalimumab-Atto | 38 | 66 | Under 11 | $67K |
| Leflunomide Generic | 37 | 86 | 11 | $758 |
| Enbrel Sureclick Etanercept | 28 | 30 | Under 11 | $137K |
| Rasuvo Methotrexate/Pf | 23 | 35 | Under 11 | $14K |
| Amjevita(Cf) Adalimumab-Atto | 22 | 27 | Under 11 | $24K |
| Actemra Actpen Tocilizumab | 20 | 22 | Under 11 | $28K |
| Xeljanz Tofacitinib Citrate | 18 | 18 | Under 11 | $45K |
| Tyenne Autoinjector Tocilizumab-Aazg | 17 | 18 | Under 11 | $19K |
Brand drugs: - claims; generic drugs: 729 claims.
Money and other things of value reported by the companies
No payments from drug or medical device companies to Manjeet S Bhamra were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.